New Delhi: US company Johnson and Johnson have asked for approval from Indian drug regulators to conduct clinical studies of Covid-19 vaccines among teenagers.
“On August 17, we send applications to the Central Medicine Standard Control Organization (CDSCO) to conduct studies of Johnson vaccine and Johnson Covid-19 in India in adolescents, 12-17 years old, said the company on Friday.
The previous company on August 7 Receiving authorization of emergency use from the drug regulator for a single-dose vaccine in the country in the country for 18 years and above, making it a fifth vaccine to get a green light.
“To reach a herd of flock, it is very important that the clinical trial of the Covid-19 vaccine continues to move forward In this population, and we remain very committed to the critical work needed to make our Covid-19 vaccine accessible evenly for all age groups “, the statement increases inventory.
J & J has an agreement with Hyderabad based on Bio E to the country.
The company does not provide details about time lines, logistics, and shipping for India.
“Sement Fig We hope to fulfill our shipping commitment, it is premature for us to speculate on our vaccine delivery time “, he said.
NOD is based on the topline efficacy and safety data from the Clinical Test Ensemble Phase 3, which shows our single-shot vaccine is 85 percent effective in preventing severe illness in all regions studied, and showing protection against hospitalization and death related to Covid-19, starting 28 days after vaccination, the company said.